{"entity":{"id":"nct05466799","kind":"trial","name":"FOLFIRINOX Versus OncoSil™ in Addition to FOLFIRINOX in Patients With Locally Advanced Pancreatic Adenocarcinoma","aka":["TRIPP-FFX"],"tldr":"A phase 2 trial of FOLFIRINOX chemotherapy in pancreatic ductal adenocarcinoma, run by OncoSil Medical Limited, active and no longer recruiting.","summary":"FOLFIRINOX Versus OncoSil™ in Addition to FOLFIRINOX in Patients With Locally Advanced Pancreatic Adenocarcinoma is a phase 2 interventional study registered as NCT05466799 by OncoSil Medical Limited, with 88 participants enrolled, started 2023-04-26 and due to reach its primary completion in 2026-01-26. Interventions recorded: FOLFIRINOX chemotherapy and OncoSil™.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05466799","url":"https://clinicaltrials.gov/study/NCT05466799"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["pancreatic","locally-advanced-pdac"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05466799","phase":"2","setting":"An Open-label, Multi-centre, Randomized Study of TaRgeted Intratumoural Placement of P-32 (OncoSil™) in Addition to FOLFIRINOX Chemotherapy vs FOLFIRINOX Alone in Patients With Unresectable Locally Advanced Pancreatic Adenocarcinoma.","sponsor":"OncoSil Medical Limited","started":"2023-04-26","startedType":"actual","enrolled":88,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05466799/","neighbours":{"cancer":[{"id":"locally-advanced-pdac","kind":"cancer","name":"Locally advanced unresectable pancreatic ductal adenocarcinoma","route":"/cancers/locally-advanced-pdac/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}]}}